[Clinical study of estramustine phosphate (Estracyt) on prostatic cancer].
Clinical effect of Estracyt was investigated in prostatic cancer patients. Twenty seven patients had been previously treated and 20 had not received prior treatment. Improvement rate of subjective symptoms was 85% in the previously untreated patients and that of objective findings was 85%, while those rates were 44% and 50% in the previously treated patients, respectively. Most of the adverse reactions were changes in mamma and mammary papilla which were considered to be due to the estrogenic activity.
Murase
T
T
Department of Urology, Nagoya University School of Medicine.
Mitsuya
H
H
Honda
N
N
Fukatu
H
H
Aota
Y
Y
Shinoda
M
M
Yoshida
K
K
Sobajima
T
T
Ohishi
M
M
Tsumura
Y
Y
D000368:Aged; D000369:Aged, 80 and over; D004961:Estramustine / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009588:Nitrogen Mustard Compounds / Q000627:therapeutic use*; D011471:Prostatic Neoplasms / Q000188:drug therapy*
D009588:Nitrogen Mustard Compounds; D004961:Estramustine